- Home
- MGRX vs GLTO Comparison
MGRX vs GLTO Comparison
Compare MGRX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- GLTO
- Stock Information
- Founded
- MGRX 2021
- GLTO 2011
- Country
- MGRX United States
- GLTO Denmark
- Employees
- MGRX N/A
- GLTO N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- GLTO Health Care
- Exchange
- MGRX Nasdaq
- GLTO Nasdaq
- Market Cap
- MGRX 25.2M
- GLTO 23.7M
- IPO Year
- MGRX 2023
- GLTO 2020
- Fundamental
- Price
- MGRX $2.62
- GLTO $11.35
- Analyst Decision
- MGRX
- GLTO Buy
- Analyst Count
- MGRX 0
- GLTO 1
- Target Price
- MGRX N/A
- GLTO $10.00
- AVG Volume (30 Days)
- MGRX 217.2K
- GLTO 7.6M
- Earning Date
- MGRX 11-13-2025
- GLTO 10-31-2025
- Dividend Yield
- MGRX N/A
- GLTO N/A
- EPS Growth
- MGRX N/A
- GLTO N/A
- EPS
- MGRX N/A
- GLTO N/A
- Revenue
- MGRX $516,030.00
- GLTO N/A
- Revenue This Year
- MGRX N/A
- GLTO N/A
- Revenue Next Year
- MGRX N/A
- GLTO N/A
- P/E Ratio
- MGRX N/A
- GLTO N/A
- Revenue Growth
- MGRX N/A
- GLTO N/A
- 52 Week Low
- MGRX $1.32
- GLTO $2.01
- 52 Week High
- MGRX $6.15
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- MGRX 59.26
- GLTO 59.85
- Support Level
- MGRX $2.08
- GLTO $12.19
- Resistance Level
- MGRX $2.61
- GLTO $18.45
- Average True Range (ATR)
- MGRX 0.25
- GLTO 2.16
- MACD
- MGRX 0.01
- GLTO 0.81
- Stochastic Oscillator
- MGRX 91.65
- GLTO 27.66
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.